肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究

目的 观察肺表面活性物质环甲膜穿刺用药结合持续正压经鼻辅助通气治疗新生儿呼吸窘迫综合征（NRDS）的可行性及临床效果。方法 80例新生儿呼吸窘迫综合征患儿随机分为气管插管给药组及环甲膜给药组，分别通过气管插管、环甲膜气管内注射肺表面活性物质100mg／kg，再联合经鼻持续正压（NCPAP）通气治疗。结果 两组患儿血气分析指标无显著性差异，两组治愈率均超90％。结论 用24G静脉套管针经环甲膜注射肺表面活性物质联合应用NCPAP治疗NRDS，同样能达到传统的经气管插管给药的效果，且具有操作简单、对患儿干扰轻微、并发症少、可重复给药等优势。

Clinical Effects of Pulmonary Surfactant in Treatment of Neonatal Respiratory Distress Syndrome

Objective To explore clinicl effects of pulmonary surfactant in treatment of neonatal respiratory distress syndrome by cricothyroid membrane puncture with 24 G needle combided with nasal continuous positive pressure ventilation（NCPAP） to neonatal respiratory distress syndrome （NRDS）. Methods Eighty cases of NRDS were randomly divided into TNP groups（PS adminstration by Tracheal intubation） and CNP groups （PS adminstration by ericothyroid membrane puncture）. PS （100 mg/kg） and NCPAP were both used in two groups. Results There is no significant difference between two groups, and the cure rate were both over 90%. Conclusion The PS application by cricothyroid membrane puncture has same clinic efficiency with that by tracheal intubation.